University of Nebraska Medical Center

DigitalCommons@UNMC
MD Theses

Special Collections

5-1-1964

Potentiation of 6-Mercaptopurine-Induced anomalies by
4-Hydroxypyrazolo-(3,4-d) pyrimidine in the fetal rat
John R. Bragonier
University of Nebraska Medical Center

This manuscript is historical in nature and may not reflect current medical research and
practice. Search PubMed for current research.

Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses
Part of the Medical Education Commons

Recommended Citation
Bragonier, John R., "Potentiation of 6-Mercaptopurine-Induced anomalies by 4-Hydroxypyrazolo-(3,4-d)
pyrimidine in the fetal rat" (1964). MD Theses. 576.
https://digitalcommons.unmc.edu/mdtheses/576

This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It
has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For
more information, please contact digitalcommons@unmc.edu.

BY

POTENTIATION OF 6-MERCAPTOPURINE-INDUCED ANOMALIES
4-HYDROXYPYRAZOL0-(3,4-d)-PY~IMIDINE IN THE FSTAL RAT

J:

'

Robert Bragonier

Submitted in Partial Fulfillment for the Degree of
Doctor of Medicine
College of Medicine, University of Nebraska
February 1, 1Y64
Omaha, Nebraska

ACKNOiiJLEDG EidEi'•T~

The author wishes to thank those people who
assisted in the preparation of this thesis.
He is grateful to the Department of Neurology
and Psychiatry for the use of its facilities; to
Miss Nadine Roesky for reproduction of the charts;
to Mrs. H.eba Benschoter and Vrs. Ada Eichhorn for
their help with photography and photographic processing; and to Miss Hoesky and

~;r.

Richard Serpan

for their technical assistance.
He is appreciative of his wife Barbara, son
Bruce, and daughter Becky for their patience and
understanding throughout the preparation of the
manuscript.
Finally, the author is indebted to Dr. Michael

J. Carver for his constant encouragement and guidance.

TABLE OF CONTENTS
Introduction

1

Historical Review

2

Experimental Teratology

2

General Considerations

2

Classification of Etiologic Factors

3

Significance of Teratologic
Investigation
6-Mercaptopurine
General Considerations

6
9
9

~i.1etabolism

10

Mechanism of Action

12

4-Hydroxypyrazolo-{ 3, 4-d)-pyrimidine

14

¥aterials and Methods

16

Hesults

19

'I
.
.
·.1scuss1on

22

Summary and Conclusions

24

Figures

25

Bibliography

34

INTHODUCTION
That 6-mercaptopurine has an inhibitory effect
on certain malignant cells is well documented.

In

microorganisms and mammalian cells, this purine analogue is oxidized to 6-thiouric acid by the enzyme
responsible for metabolism of purine bases, xanthine
oxidase.

Certain compounds which inhibit xanthine

oxidase potentiate the antitumor effect of 6-rnercaptopurine noted above.
Six-mercaptopurine has also been shown to produce malformations in fetal rats when injected during
the proper stage of embryonic development.

Demonstra-

tion that 4-hydroxypyrazolo-(3,4-d)-pyrimidine, a
potent xanthine oxidase inhibitor, is non-teratogenic
but capable of potentiating the teratogenic effect
of 6-mercaptopurine would draw an interesting parallel
between the action of 6-mercaptopurine against rapidly
growing, relatively undifferentiated cells, out of
control, as in malignancy, and under control, as in
the developing fetus.

The purpose of this investi-

gation was to demonstrate in this manner that such a
parallel does exist, in order to clarify the mode of
teratogenic action of 6-mercaptopurine.

1•

HISTOtilCAL HEVIEH
Experimental Teratology
General Considerations
Congenital malformations have in recent years
been recognized as one of the leading causes of infant
mortality and morbidity.

In earlier times the con-

genitally deformed were considered monstrosities, evil,
objects of the "wrath of God 11 or "acts of the devil".
¥any were non-viable and chiefly of interest to anatomists and pathologists.

However, modern medicine has

effected such changes in the patterns of human morbidity and mortality tnat ten times as many children
now die as a result of congenital malformations as of
five contagious diseases once greatly feared ll).
This relative increase in the incidence of congenital
malformations has placed added emphasis on clinical
and experimental investigation in the field.
Whenever a medical problem exists, reproduction
of the pathologic phenomena in animal experiments is
of value.

In the past, however, experimental produc-

tion of congenital malformations has generally failed
to satisfy those interested in the etiology of anomalies in children, although these investigations have
been performed in lower animals for nearly a century.
Complaints have commonly been that mammals have a
2.

co~pletely

different maternal-fetal relationship, or

that agents used to produce anomalies are unphysiolog1c
and without parallel in the human.

The latter criti-

cism was applied to the first teratologic metnod practiced in mammals during the first decade of this century:

the administration of x-rays to the pregnant

mother!

Not until about two decades ago when it

became possible to produce malformations experimentally
in mammals by maternal dietary deficiencies were these
arguments to some degree overcome.
Classification of Etiologic

Factor~

The field of experimental mammalian teratology
is generally acknowledged to date from Hale's work
reported in

1~33

(2); piglets from a sow raised on

a vitamin A-deficient diet were born without eyes.
Since that time literature in the field has grown
quite extensive.

Only a brief classification of

factors known to cause experimental congenital malformations will be presented here; excellent review
articles have been prepared by Kalter and Warkany (lJ,
~arkany

I.

and Kalter (3J, Hillemann t4J, and
Genetic factors (3,4)
A.

Gene mutations

B.

Chromosome abnormalities
1.

Chromosome excess
3.

~ilson

(SJ.

c.

2.

Chromosome deficiency

3.

Translocation of genes

4.

Transduction of genes

5.

Deletion of genes

6.

Crossing-over of genes

Embryonic instability, or inheritance of
susceptibility to congenital
deformity ( 6)

II.

Nutritional factors { 1, 4)

A.

Vitamin deficiency or antagonism
1.

Vitamin

2.

Thiamine

3.

Riboflavin ( 7 )

4.

Niacin

5.

Pantothenic acid

6.

Cobalamin (!U)

7.

Folic acid ( 11-14)

8•

Vitamin

c

9.

Vitamin

J)

1 i.).

B.

( 0)

{15)

Vitamin E ( 16)

Vitamin A {17)

Amino acid antagonism
1.

D.

(2 )

Vitamin excess
1.

c.

A

Leucine (18)

Fasting

(6,l~J

4.

{~)

III.

E.

Nucleic acid antagonism (20-23)

F.

Galactose \24)

Hormonal factors (1,4)
A.

Pituitary preparations
1.

2.

IV.

Anterior pituitary extract
a.

Growth hormone

b.

ACTH

Posterior pituitary extract

B.

Estrogen

c.

Insulin deficiency and excess

D.

Thyroid deficiency and excess

E.

Corticosteroid hormones

(2~,26)

Mechanical and physical factors
A.

Amniocentesis (27)

B.

Direct physical trauma or mechanical
injury (4)

V.

VI.

c.

Hyper- and hypothermia (28)

D.

Anoxia {2:::;)

Antibiotics (4)
A.

3treptomycin

B.

Tetracycline

c.

Penicillin

Inorganic materials
A.

Carbon monoxide

B.

Carbon dioxide
5.

(4j

VIL.

c.

Thallium and lead nitrates

D.

Boric acid

E.

11

Heavy water 11 tD 2 o)

Organic materials and drugs
A.

Trypan Blue dye {3UJ

B.

Nicotine t31)

c.

5-Hydroxytryptamine {32, 33)

D.

Colchicine (34)

E.

Nitrogen mustard (35,22)

F.

Triethylenemelamine (TEM) l36)

G.

Triethylenephosphoramide {TEPAJ {36)

H.

Various other drugs, factors and
ch emi ca 1 s ( 1 , 4 )

VIII.

Radiation (37,3dJ

Significance of Teratologic Investigation
From the preceding representative but incomplete
outline, it can be seen that a large variety of
methods are now available for the experimental production of congenital malformations.

The types of

anomalies produced and structures affected are
equally as variable.

In addition, malformations are

but one manifestation of reproductive failure, and
these methods are usually also capable of causing
other disturbances such as sterility, abortion, fetal
resorption, or neonatal death.
6.

It is in fact

relatively easy to interrupt pregnancy by environmental interference; it is more difficult to obtain
viable offspring with congenital malformations, since
this requires an experimental arrangement that permits
damaging the embryo without killing it.

To achieve

such balance, the timing, the type of teratogenic
agent, and its dosage must all be coordinated.
These varied investigations have demonstrated
that each embryologic process has its critical period;
damage done by a teratogenic procedure depends largely
upon which structures are undergoing critical development at the time the procedure is applied.

Similarly,

damage to those structures cannot be produced after
the critical period of development has passed.

On the

other hand, the investigations have clearly shown that
teratogens also have their specificities.

Acute

agents attack the embryo once and demonstrate that
specific malformations are produced at particular
embryologic stages, while other agents are chronic,
staying with the mother throughout pregnancy and
acting only when the embryo is sensitive to them.
addition, agent specificity of different teratogens
cannot be denied.

While one agent may produce a

given anomaly with great effectiveness, another may
not, even though the agents are applied at the same
7.

In

gestational stage.
The action of chronic teratogens is comparable
in some respects to that of genes; these hereditary
factors are also present throughout the organogenetic
period but appear to act only at certain stages of
development.

All teratogens (both acute and chronic)

have other points of resemblance to genes.

For instance,

some induced malformations simulate hereditary defects,
that is, are
11

11

phenocopies 11 •

Just as genes often have

pleiotropic 11 effects, so teratogens may produce

variable syndromes, or cause malformations in a variety
of organs that seem unrelated to each other in postnatal life.

From"these points it may be reasonable to

deduce that environmental factors sometimes produce
phenocopies by altering developmental processes in
the same way gene changes or mutations do.

Since little

is known about the biochemical reactions of genes that
lead to malformations, a knowledge of the reactions
that lead to their phenocopies may be of value in
elucidating the mode of action of faulty genes.

For

example, vitamins act as prosthetic groups in enzymes
engaged in vital metabolic activities; if enzymes participate in biochemical reactions that determine
channels of embryonic development, then absence of a
vitamin may result in the interruption of a biochemical
8.

sequence, much as the action of a biochemical mutant
does, which eventually leads to abnormal channels of
development (1).
These methods for producing specific malformations have thus proved of great value as models whereby
general mechanisms leading to congenital malformations
in mammals, especially humans, can be studied.
6-Mercaptopurine
General Considerations
The synthesis of 6-mercaptopurine (6-MPJ was
first described by Elion and Hitchings {3Y) in 1Y52.
It had originally been studied during the systematic
investigation of substituted purines for antagonists
of nucleic acid synthesis (40).

Attention was focused

on the drug when early reports of its inhibitory
effects on microorganisms {41), experimental tumors
{42), and mouse leukemias {43) appeared, and in 1Y53
temporary remissions in certain cases of acute human
leukemia following 6-MP therapy were reported (44).
Since that time, clinical use of this purine analogue
has been well documented and its biologic and biochemical effects extensively studied (45).
The teratogenic action of 6-MP in mammals was
first reported by Thiersch in

1~54

{46).

Following

a single oral ingestion of the drug at varying times
9.

in their pregnancy, female rats gave birth to large
numbers of stunted or stillborn fetuses.

No gross

malformations were noted in the survivors, but doses
administered were small.

Fetuses were most sensitive

to the effects of the drug on the seventh and eighth
day of gestation.
In 1Y56 Didcock and coworkers attempted to interrupt pregnancy in rabbits with intra-amniotic injections of 6-MF {47).

The increased number of abortions

noted was accompanied by the unexpected presence of
fetuses with congenital malformations; the fetuses
were viable at term.
A detailed study of the teratogenic effects of
antitumor compounds was published by Murphy in 1Y60 (20).
She reported observing fetal skeletal malformations
following single intraperitoneal injections of 6-VP
into pregnant rats on the twelfth day of gestation.
Sross anomalies were carefully recorded and consisted
of stunting, pointed noses, shortened extremities,
fused digits, and rudimentary rear legs and tail.

This

paper provided the technical basis for the present
investigation.
Metabolism
Six-mercaptopurine closely follows the known
pathways for anabolism and catabolism of purine bases.
10.

The analogue is a competitive inhibitor of xanthine
oxidation (48) and is oxidized to 6-thiouric acid by
microorganisms and mammalian cells

(4~,

50).

Desulfurization occurs in mice, as indicated by
sulfate-s

35

excretion and labeling of nucleic acid
•
•
f rom 0-,,1
,. Mp -v-1,,
;.., " 14 l' 45) ; l a.oe
' 1 ed
an d guanine
a d enine
hypoxanthine and purine nucleotides have also been
recovered in microorganisms following labeled 6-MP

administration (49).

In addition to 6-thiouric acid,

6-methylmercaptopurine has been identified as an
excretion product of 6-MP metabolism (51), and a
considerable amount of the drug is excreted in the
urine unchanged or bound as a glucuronide (52,53).
Conversion of 6-MP to its ribotide has been reported
(54-56), indicating that the analogue undergoes at
least the initial steps toward incorporation into
nucleic acids.

This enzymatic conversion is illus-

trated in Chart 1, while Chart 2 summarizes the known
and postulated pathways of 6-LlP metabolism (57).
SH

N~N~ :-OCQH6

~".Jl
N
NI
H

Mg+:

0-®·®
OH OH

~):)

+pp;

®-OCHQO
OH OH

Chart 1. ~nzymatic synthesis of b-mercaptopurine ribonucleotide by reaction of the base with 5-phosphoribosyl-1-pyrophosphate.
11.

Anabolism
MP ribonucleoside
phosphorylase

~

"''---.. ..........._lkinaseJ

~yrophosphorylase

6-Mercaptopurine

inosinic
acid

M~

~

ribonucleotide

---

\

~
~ ----polyphosphates
polynucleotides

Catabolism
xanthine
oxidase
6-thioxanthine

6-~ercaptopurine

L

xanthine
oxidase

>

6-thiouric
acid

6-methylmercaptopurine
sulfate; hypoxanthine; anabolic and catabolic products of purine metabolism

Chart 2.

The metabolism of 6-mercaptopurine in vivo

Mechanism of Action
Prior to 1Y4d it was assumed that nucleic acid
purines were entirely synthesized de nova from formate,
glycine, carbon dioxide, and ammonium salts.

At that

time a report appeared which indicated that preformed
purines can be interconverted and incorporated into
nucleic acids {5d); it was eventually supported by
further investigation

t5~,6UJ.

The exact mechanism

of action of 6-MP is unknown, but the best theory is
based on the above premise.
Six-mercaptopurine and other analogues of adenine
and guanine are believed to interfere with incorporation
12.

of preformed purines to form nucleic acids and
purine-containing coenzymes (2u).

Bacterial data

indicate that the primary site of action is at the
interconversion, through a hypoxanthine derivative,
of guanine and adenine ribonucleotides.

Formation

of the ribonucleotides is competitively inhibited by
6-iJ'P ( 61 j.

The apparent inl11bi tion of de

purine synthesis by

6-~P

~

may be related to interference

with the conversion of inosinic acid to appropriate
adenine and guanine derivatives, although there is
evidence that, in leukemic blood cells, enzyme inhibition by 6-MP occurs prior to the formation of inosinic
acid (62).

Another alternative is that blocking of

~~purine

synthesis by

6-f11~F

is a manifestation of

what is now termed feedback inhibition or end-product
inhibition (57).

A number of investigators have

recognized that unlabeled purines prevent or depress
the incorporation into the purine structure of labeled
precursors.
Ellis and LeFage (63) have shown that cells
susceptible to 6-thioguanine incorporate significant
amounts of the purine antimetabolite into their nucleic
acids, while resistant cells incorporate only minor
amounts.

The possibility still remains that in addi-

tion to competitively inhibiting normal nucleic acid
13.

synthesis in the manner described above, 6-MP may
actually be incorporated in toto in place of adenine
or guanine into the nucleic acid molecule, as is
thioguanine.
No studies have been performed to determine the
mechanism of action of 6-MP against developing fetal
cells; it has been assumed that the drug acts in a
similar manner against normal and malignant cells.
The present investigation was designed to test that
assumption.
4-Hydroxypyrazolo-(3,4-d)-pyrimidine
In an attempt to correlate details of chemical
structure with activity, a systematic investigation
of purines and their analogues has been under way
for a number of years (64,65).

In the process, syn-

thesis of the pyrazolo-(3,4-d)-pyrimidine ring system
was undertaken to provide new compounds isomeric with
various biologically active purines.

The pyrazolo-

(3,4-d)-pyrimidines differ from the purines by virtue
of a pyrazole rather than imidazole ring attached to
the pyrimidine moiety (66).

At least one of these

compounds, 4-aminopyrazolo-(3,4-d)-pyrimidine, an
adenine isomer, has demonstrated significant antitumor
activity (67).
At the same time in parallel studies, a substantial
14.

number of these compounds were found to be inhibitors
of xanthine oxidase-catalyzed reactions {6d).

Since

this enzyme catalyzes the oxidation of 6-MP to 6-thiouric acid (SU), Elion and coworkers decided to determine whether 6-MP oxidation could be inhibited in yivo,
and whether the apparent potency and possibly the
chemotherapeutic index of 6-MP could be altered by
this means (52).

Four-hydroxypyrazolo-(3,4-d)-pyri-

midine (HPP) was the compound chosen for trial; it
had high potency as a xanthine oxidase inhibitor, only
moderate toxicity, and no antitumor activity against
the test systems (67).

Chart 3 provides a comparison

of the structures of 6-MP and HPP.
6SH
IN
I
2C

0-......s

40H

C-N

II

~H

C-N/
~N/4
9
3
H

6-MF
Chart 3.

. . . . c,

7

5 N.--

8

I

6 C:-...

9

3

C-C~

II

N2

C-N/

"- N....-8
7

H
I

HPP

Comparison of the structures of 6-MP and HPP.

Experiments performed on tumor cells in both the
mouse and human demonstrated that inhibition of xanthine
oxidase activity is attained in vivo when HPP is
administered, and that such inhibition results in a
decrease in the metabolic destruction of 6-MP (52).

15.

MATEN:IALS AND METHODS
Pregnant albino rats (Sprague-Dawley strain) were
obtained from the Holtzman Xat Company, Madison, Wisconsin.

The day the animals were sperm positive was

called gestation day zero.

They were housed no more

than four to a cage in air conditioned quarters and
given Kockland rat chow and tap water ad libitum.
On gestation day 12, all animals were injected
intraperitoneally with a l.J ml suspension of 6-MP 1
and/or HPP 2 in the approximate dosages listed on the
following page in Table I.

Amounts of each drug

injected were one fifth the values listed, as all rats
weighed approximately 200 grams, and prior experiments
had demonstrated that more precise dosages were not
necessary to assure uniform production of anomalies.
The drugs were suspended in carboxymethylcellulose
due to their insolubility at a physiologic pH.

use

of this inert gum as a vehicle assured more uniform
dosages; its viscosity minimized error caused by
settling out of the drugs.
On gestation day 20, 1-2 days before parturition,
the rats were sacrificed by cervical dislocation and
the fetuses delivered by Caesarean section, a procedure
1.
2.

Nutritional Biochemicals Corporation, Cleveland, Ohio.
Aldrich Chemical Company, Mil·waukee, '.Visconsin.
16.

Table I
Dosaae Schedule
Dosage
(mg/kg)

Drug Injected

No. Paternal
Hats Injected

Control-No Injection
Contra 1-CMC-l:( Ca rboxymethyl cellulose)

Total N c>".
Fetuses
Examined

12

125

13

114

6-Percaptopurine ( 6-'.\P)

60

15

127

4-Hydroxypyrazolo( 3, 4-d )-pyrimidine (HFF)

120

5

48

120

5

57

15

y

83

30

lu

101

15
3U

y

SJ6

7'd

7 51

6-i.~t-'

plus

6U

I-lFF

HFP
6-!''l--

plus

HFP
Totals

*

All drugs were injected in CMC, lU mg/ml.

necessary as experimental young allowed to deliver normally were eaten by the mother.

The fetuses were

examined closely for evidence of malformations or stillbirth, and the uteri, for resorption sites.

Placentas

were separated from the fetuses, and the latter were
blotted dry, weighed on a Mettler semi-micro balance,
and quick-frozen for subsequent study.

NO

further

processing was done prior to x-ray examination.
Fetuses to be stained were transferred to
17.

Y5){,

ethanol for at least 72 hours to assure adequate
fixation.

They were then carefully skinned and placed

in several changes of
clearing.

l~

potassium hydroxide for

This step required 4-7 days; unless the

soft tissues were entirely

transl~cent,

they would

take up stain.
After clearing 1 the fetuses were placed in
Alizarin

~ed

3 stain in

l~

U.Ul~

potassium hydroxide until

the desired depth of staining was noted {approximately
6-12 hours).

Clearing was completed in several

changes of 2U parts glycerin: 80 parts
hydroxide.

l~

potassium

The fetuses were then transferred through

a graded glycerin series and stored in pure glycerin
{6~).

18.

riE..:lJLT::l

Figure 1 illustrates the gross appearance after
ethanol fixation of a control fetus and one whose
mother r-eceived a teratogenic dose of
Though viable at the

ti~e

6-l~'<P

\60 mg/kg).

of Caesarean section, the

latter fetus demonstrates stunting of growth, generalized throughout the body but propor-tionally more
severe at the caudal end.

Gross shortening of the

tail is noted, together with retardation or absence
of digital development, or syndactyly.

The digital

anomaly is more pronounced on the hind legs; at least
two toes commonly appear on the forefeet, whereas
complete fusion or lack of differentiation of adjacent phalanges and metatarsals is the rule on the
hind feet.
The presence of an umbilical hernia can be seen;
although appearing inconsistently, this malformation
was present in over half the fetuses examined, and the
abdominal wall defect was in some instances quite
extensive.
a re

11

Other inconsistently appearing defects

s c r a mb 1 e d 11 s t er nab r a e l 71.J ) and an as a r ca •

In

many fetuses sternal ossification centers could not
be seen, but wnen present they were often deformed and
irregular.

Anasarca was noted only in those fetuses

most severely affected.
19.

X-rays were taken at different milliamperage,
time, and kilovoltage settings and on several types
of film to obtain best possible skeletal detail.
The films were printed directly (Figure 2) or photographed and the resulting negative printed (Figure 3).
Neither negative nor positive print adequately demonstrates fetal structJre due to lack of bone density
at this stage of development, but stunting of growth
and abnormalities of the ribs and spine can be seen.
Differential staining proved to be the better
method for visualization of bony structure.

Com-

parison of the stained skeletons of control and
experimental fetuses reveals in the latter retardation
or absence of ossification of metacarpal, metatarsal,
and phalangeal centers (Figures

4,~,7)

and absence of

one of the two lower leg bones (Figure 7).

Both radius

and ulna, however, were invariably present (Figure 5).
'P.arked branching and fusing of the ribs can be seen
(Figure 5), and a degree of spina bifida is suggested
by divergence and irregularity of the lateral processes of the lumbar and sacral vertebrae, with duplication of the central vertebral body (Figure 6).
Of note was the consistency of the above findings.
Although malformations varied to a small extent in
severity (probably due to differences in absolute drug
20.

dosage between litters and to variations in fetal
susceptibility within the litter), no unaffected
fetuses were obtained from maternal animals receiving
6-MP at the teratogenic dosage.

At the other extreme,

no increase in intrauterine death was apparent, as
judged by the lack of increase in numner of stillbirths or uterine resorption sites.
One-fourth the teratogenic dosage of

6-~F

(15

mg/kg) caused no apparent change in fetal development;
no malformations could be found (Figure 8), and fetal
weight was not significantly different from control
values 1 • The same results were obtained after the
injection of HPP at 30 and 120 mg/kg.
6-~P

(15 mg/kg) and

~alformations

H~P

However, when

(30 mg/kg) were given together,

identical to those obtained with the

teratogenic dose of 6-I5P (60 mg/kg) alone were noted
(Figures

~,Y).

The combination of the teratogenic

dose with HPP (120 mg/kg) resulted not in malformations
but in rapid fetal death.

1.

Unpublished data.
21.

D ISCiJSS ION
Four-hydroxypyrazolo-(3,4-d)-pyri~idine

has

previously been reported to potentiate the antitumor
action of 6-mercaptopurine.

The data above indicate

that this xanthine oxidase inhibitor has a similar
ability to potentiate the teratogenic action of 6-MP.
This finding suggests the possibility that 6-MP acts
at a similar site in malignant and fetal cells and
establishes a precedent for consideration of the
mechanism of action in both instances as identical.
That anomalies produced following 6-YP administration are due to 6-LlP rather than one of its metabolites (53) has not yet been proven, but this investigation indicates the excretory end product, 6-thiouric
acid, and the intermediary metabolite of xanthine oxidation, 6-thioxanthine (57), are not the responsible
agents.

If they were, addition of HPP would prevent

or lessen the anomalies obtained, since 6-thiouric
acid and 6-thioxanthine would not be formed enzymatically from 6-MP.

On the other hand, if 6-MP or one

of its metabolites from pathways other tnan that
involving xanthine oxidase were the teratogenic agent,
addition of HFF would increase the severity of the
anomalies or increase the effectiveness of 6-MP at a
lower dosage.

Both were the case.
22.

When HPP was added

to the teratogenic aose of

6-~P,

fetal death occurred

shortly after administration, as demonstrated by small
fetal size and extensive resorption.

6econdly, fetal

anomalies obtained with one-fourth the teratogenic
dose of 6-MP in combination with HPP resembled those
obtained with the teratogenic dose of 6-MP alone.
On the basis of these findings, further studies
are being carried out to determine the exact nature
of 6-MP teratogenesis.

It is hoped that this investi-

gation may eventually shed light on the broader problem of drug-induced teratogenesis in the human.

In

addition, since a parallel has been established between
action of

6-~P

against fetal and malignant cells,

results obtained from study of 6-MP-induced congenital
anomalies may find secondary application to problems
in the field of cancer chemotherapy and finally, help
to elucidate the larger problem of the nature of
malignant growth in general.

23.

SUMl~ARY

AND CONCLUSIONS

Congenital malformations are produced in fetal
rats by a single intraperitoneal injection of the
purine analogue 6-mercaptopurine into pregnant rats
at the critical stage of gestation.

Photographs and

descriptions of these malformations are presented.
Administration of 4-hydroxypyrazolo-lJ,4-dJpyr1mi6ine

(a

xanthine oxidase inhibitor) with non-

teratogenic doses of 6-mercaptopurine results in
similar congenital malformations.

Combination of the

former drug with teratogenic doses of the latter
causes fetal death.

It has thus been demonstrated

that 4-hydroxypyrazolo-(3,4-d)-pyrimidine potent1ates
the teratogenic action of 6-mercaptopurine, as well
as its antitumor activity, which has been previously
reported.

24.

Figure 1.

Gross appearance after ethanol fixation

of a control and experimental fetus at twenty days
of gestation.

Stunting of growth, shortening of

the tail, retardation or absence of development of
hind legs and feet, and umbilical hernia can be
clearly seen.
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CONTROL

6-MP
60 MG /KG

-----~----

-

-

Figure 2.

Direct print taken from an x-ray of a

control and experimental fetus.

The x-ray film was

exposed at 30Umilliamperes, 3U kilovolts for one
second.

Although indistinct, stunting of growth

and abnormalities of the ribs and spine can be
seen.

26.

Figure 3.

Indirect print of fetuses in Figure 2.

The x-ray film was photographed and the resulting
negative printed.

Original x•ray exposure was 3UU

milliamperes, 30 kilovolts, for 2.5 seconds.
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CONTROL

6-MP
60 MG/KG

Figure 4.

Differential staining of a control and

experimental fetus.

This method provides much

better visualization of skeletal detail.

Back-

lighting was produced by photographing the fetuses
on an x-ray view box.

--

CONTROL

6-MP
60 MG/KG

--:

Figure 5.

Close-up view of the experimental

fetus pictured in Figure 4.
branching and fusing of ribs.

Note the marked
Both radius and

ulna can be identified on the right, but one of
the two lower leg bones (probably the fibula) is
characteristically absent bilaterally.

Figure 6., Close-up view of the spines of exper1mental { 6-f·!}, 6U mg/kg) and control fetus es.

The

experimental fetus has been bisected transversely
to allow viewing of the spine in one plane.
Lateral processes of the lumbar and sacral vertew
0

•

brae are irregular and can be seen to

diver~e;

together with duplication of the vertebral centra,
this suggests a degiee of spina bifida.

•

Figure 7.

Hind legs from control and experimental

{6-IAP, 6U mg/kg) fetuses.

rtetarded or absent

development of ossification centers, stunting of
growth, and absence of one lower leg bone (probably
the fibula) are all visible.
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Figure

a.

Effect of HPP.

It is evident that

while 6-MP (15 mg/kg) and HPP (3U and 12U mg/kg)
had no effect on the fetus, the administration of
HPP (30 mg/kg) in combination with 6-MP (15 mg/kg)
resulted in anomalies identical in type to those
caused by 6-MP (6U mg/kg), but to somewhat less
severe a degree.

32.
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CONTROL

6-MP
H Ioc
60 MG/KG 120 MG/KG
i

,,

"'

HPP
6-MP
6-MP 15 MG/KG+
30 MG/KG 15 MG/ KG
HP P 30 MG I KG

Figure Y.

Fetus whose mother received 6-UF llS

mg/kg) and

H~P

fetus.

(30 mg/kg) compared with a control

All skeletal anomalies previously described

with 6-rliP (60 mg/kg) can be identified in this.
fetus, such as divergence and irregularity of the
lateral processes of the lumbar and sacral vertew
w

•

brae with double vertebral centra, marked branching
and

f~sing

of the ribs, absence of one of the two

lower leg bones, and lack of digital aevelopment,
with retardation or absence of ossification of
metacarpal, metatarsal, and phalangeal centers.

'·

..
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